The National Rheumatoid Arthritis Society (NRAS) has expressed their frustration at NICE’s provisional decision not to allow patients with rheumatoid arthritis to routinely switch from one Anti-TNF drug to another. This is the second time NICE has appraised the sequential effectiveness of multiple biologic therapies following NRAS’s successful appeal of negative NICE guidance on switching in 2007…
